Structure via PubChem · Public domain (PubChem)
cabergolina
Sign in to saveAlso known as Cabaser®, Caberlin®, (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea, 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea, (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide, (8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
farmaco
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 477165198
- Drug.image
- Cabergoline Skeletal.png
- Drug.image_class
- skin-invert-image
- Drug.width
- 268
- Drug.image2
- Cabergoline_3D_Xtal_ballandstick.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 260
- Drug.tradename
- Dostinex, others
- Drug.DailyMedID
- Cabergoline
- Drug.routes_of_administration
- Oral
- Drug.ATC_prefix
- G02
- Drug.ATC_suffix
- CB03
- Drug.legal_AU
- S4
- Drug.legal_US
- Rx-only
- Drug.bioavailability
- 50–80%
- Drug.protein_bound
- Moderately bound (40–42%); concentration-independent
via Wikipedia infobox
Chemical data
- Formula
- C26H37N5O2
- Molecular weight
- 451.6 g/mol
- IUPAC name
- (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
- SMILES
- CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C
- InChIKey
- KORNTPPJEAJQIU-KJXAQDMKSA-N
- XLogP
- 3.4
- Polar surface area
- 71.7 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1996
- Admin. routes
- oral
- Indications
- infertility, restless legs syndrome, cocaine dependence, obesity
via ChEMBL · EBI
Research
2,371 papers- Cabergoline in acromegaly.Pituitary · 2017
- Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial.Obstetrics and gynecology · 2023
- Cabergoline Use and Pregnancy Outcomes: A Systematic Review.Birth defects research · 2025
- Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.Journal of the International AIDS Society · 2019
- Pituitary acting drugs: cabergoline and pasireotide.Pituitary · 2022
via PubMed
Wikidata facts
- Mass
- 451.294725
- Has use
- medication
Show 8 more facts
- chemical formula
- C₂₆H₃₇N₅O₂
- canonical SMILES
- CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C
- isomeric SMILES
- CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C
- World Health Organisation international non-proprietary name
- cabergoline
- defined daily dose
- 0.5
- subject has role
- antineoplastic
- significant drug interaction
- chlorpromazine
- Commons category
- Cabergoline
via Wikidata · CC0
Article · Italiano
La cabergolina è un derivato dell'ergot, che funziona come agonista dei recettori D2 della dopamina. Il principio attivo si utilizza contro la malattia di Parkinson in aggiunta alla levodopa. Alcuni studi sui ratti hanno dimostrato che la cabergolina ha un effetto inibitorio diretto sulle cellule dell’ipofisi che producono l'ormone prolattina. Viene usata come farmaco di prima scelta nella gestione dei prolattinomi, grazie alla sua affinità per i recettori D2, e grazie agli effetti collaterali meno gravi e un dosaggio più conveniente rispetto alla vecchia bromocriptina. È stata brevettata nel 1980 e approvata per uso medico nel 1993.
Abstract from DBpedia / Wikipedia · CC BY-SA